Dr. Phd Mark

Dr. Phd Mark

Professor

Creighton University
390 SW Edgecliff Road, Portland, United States of America, 97219

plus Speciality

MEDICAL ENTERPRENEURSHIP

Biography:

Mark J. Ahn, Ph.D. is President & Chief Executive Officer, and Director of Galena Biopharma (Nasdaq: GALE) and Professor (adjunct), Biosciences, Creighton University. Prior to Galena, Dr. Ahn was Principal at Pukana Partners, Ltd. that provides strategic consulting to life science companies; and served as Chair, Science & Technology Management, Victoria University at Wellington, New Zealand. Dr. Ahn was also founder, President, and Chief Executive Officer of Hana Biosciences. He also served as Vice President, Hematology and corporate officer at Genentech, Inc., as well as held positions of increasing responsibility at Amgen and Bristol-Myers Squibb Company; and served in the US Army. Dr. Ahn also serves on public and venture capital-backed Board of Directors for Access Pharmaceuticals, Mesynthes and Scribes STAT. Dr. Ahn is the author of over 50 peer reviewed journal articles and books including Making the Case for Biotechnology (Logos Press). Dr. Ahn received a BA and MBA from Chaminade University; and MA from Victoria University. He was a graduate fellow in Economics at Essex University, and obtained a Ph.D. from the University of South Australia. Dr. Ahn is a Henry Crown Fellow at the Aspen Institute.

Academic positions:

1. Creighton University, Biosciences, adjunct faculty, 2009-present
2. Willamette University, Associate Professor, Global Management & Innovation, 2009-2011. Outstanding Scholarship Award 2011.
3. Victoria University of Wellington, Professor and Chair, Science & Technology Entrepreneurship with a joint appointment from the faculties of Commerce & Administration and Science, 2007-2009
4. University of Notre Dame, adjunct faculty, 2002-2005
5. College of New Jersey, adjunct faculty, 2000-2002
6. National School of Public Health, MEDUNSA, adjunct faculty, 1999-2001
7. Berkeley College, adjunct faculty, 1998-2000

Research interests:

biotechnology, oncology, entrepreneurship

Any other information:

Publications

1. Bot A, Ahn M, Bosch M, Brockstedt D, Butterfield LH, Cornforth A, Harrop R, Kast WM, Koya R, Marincola F, Margolin K, McCoy C, Pawelec G, Rothman J, Schlom J, Srivastava P, Wallis S, Walter S, Wang E, Waslif J. 2012. A Novel Series of Conferences Tackling the Hurdles in Front of Translating Novel Cancer Immunotherapies, Journal of Translational Medicine, 10(1): 218, doi:10.1186/1479-5876-10-218.
2. York, A., Dunham, L. & Ahn, M. 2012. Vertical vs. Horizontal Integration in the Biopharma Industry: The Link Between Acquisition Announcements and Stock. Market Performance, in: Cooper, C.L. & Finklestein, S. (Eds) Advances in Mergers and Acquisitions, Bingley, UK: Emerald Publishing Group, 10, 121-143.
3. Mazanet, R. & Ahn, M. 2012. Novel Adjuvant Treatment for Early-Stage Breast Cancer. Drug Discovery & Development.
4. Ettner, L. & Ahn, M. 2012. Wrangling Along: Governance and Leadership Principles and Applications, in: Wells, P. & Mueller, J. Cases of Contemporary Challenges in Corporate Governance: Governance in Public Sectors, Oxford, UK: RS RossiSmith, 151-160.
5. Ahn, M., Ettner, L. & Loupin, A. 2012. Values v. Traits-Based Approaches to Leadership: Insights from an Analysis of the Aeneid, Leadership & Organization Development Journal, 33(2), 112-130.
6. Dunham, L., Ahn, M. & York, A. 2012. Building a Bioeconomy in the Heartland: Bridging the Gap Between Capabilities and Perceptions. Journal of Enterprising Communities, 6(1), 84-100.
7. Ahn, M., Hajela, A. & Akbar, M. 2012. High Technology in Emerging Markets: Building Biotechnology Clusters, Capabilities and Competitiveness in India, International Journal of Emerging Markets, 4(1), 23-41.
8. Ahn, M., Couch, R. & Wu, W. 2011. Financing Development Stage Biotechnology Companies: RMs (Reverse Mergers) vs. IPOs (Initial Public Offerings), Journal of Health Care Finance.
9. York, A. & Ahn, M. 2011. University Technology Transfer Office Success Factors: A Comparative Case Study, International Journal of Technology Transfer, 1/2, 26-50.
10. Gray, B., Collier, A. & Ahn, M. 2011. Does University-Based High-Technology Transfer Enhance Small and Medium- Sized Enterprise (SME) Performance? Small Enterprise Research, 18(1), 2-18.
11. Ahn, M. & Ettner, L. 2011. “Using the Humanities to Teach Values-Based Leadership”, in: Wankel, C. and Stachowicz- Stanusch, A. (Eds), Effectively Integrating Ethical Dimensions into Business Education.
12. Ahn, M. & Ettner, L. 2011. From Classical to Contemporary Leadership Challenges: A Values-Based Leadership View, Journal of Leadership Studies, 5(1), 6-22.
13. Zwikael, O., Elias, A. & Ahn, M. 2011. Stakeholder collaboration and engagement in virtual projects. International Journal of Networking and Virtual Organisations.
14. Ahn, M. & Zwikael, O. 2010. Crossing the Chasm: Technological Invention to Product Innovation, International Journal of Commerce and Management.
15. Ahn, M., Frederickson, L. Borman, B. & Bednarek, R. 2010. Eye Health in New Zealand: A Study of Public Knowledge, Attitudes, and Practices Related to Eye Health and Disease, Health Education.
16. Ahn, M., Meeks, M., Bednarek, R., Ross, C. & Dalziel, S. 2010. Towards a High Performance Bioeconomy: Determining Cluster Priorities and Capabilities in New Zealand, International Journal of Commerce and Management, 20(4), 308- 330. Outstanding Paper Award Winner at the Literati Network Awards for Excellence 2011.
17. Ahn, M., Ackerley, D., Davenport, S., & Bednarek, R. 2010. ‘Fodosine at IRL (Industrial Research Limited): From Invention to Innovation’ in: Hunter, I. & Morris, K. (Eds) New Zealand Case Series: Innovation and Entrepreneurship, Auckland: Auckland University Press.
18. Zwikael, O. & Ahn, M. 2010. The Effectiveness of Risk Management: An Analysis of Project Risk Planning Across Countries and Industries, Risk Analysis, doi: 10.1111/j.1539-6924.2010.01470.x
19. Ahn, M., Ackerley, D., York A., Davenport, S. & Bednarek, R. 2010. From Novel Biotechnology Platform to Globally Competitive Cancer Company: Proacta, Inc. International Journal of Case Studies in Management.
20. Ahn, M., Alvarez, M., Meyers, A., & York, A. (Eds.) 2010. Building the Case for Biotechnology. Logos Press: Washington, DC. Co-authored 8 of 22 cases:
(i) The Founding and Growth of On-Q-ity: Developing Advances in Personalized Medicine by Daniel Dornbusch and
Mark Ahn
(ii) Tysabri Re-launch Decision: Promise and Perils of Addressing Unmet Needs by Mark J. Ahn and Laura Ueki
(iii) Dyadic International: From Doom to Dawn—What’s Next? by Polly Rizova, Adelaida Patrasc, and Mark J. Ahn
(iv) Oxigene: Realizing Value from Multiple Technology Platforms by Mark J. Ahn and Anne S. York
(v) Medarex: Realizing its Potential? by Mark J. Ahn, Wei Wu, and Masum Rahman
(vi) OraPharma: Reformulation of an Existing Product by Payam Benyamini and Mark J. Ahn
(vii) Genentech-Roche: Will Innovation Whither? by Mark J. Ahn, Anne S. York, David Ackerley, and David Lee
(Viii) Myogen-Gilead: Are We There Yet? by Mark J. Ahn, Arlen Meyers and Travis Cook
21. Ahn, M., Sutherland, K., & Bednarek, R. 2010. Negotiating, Power and Strategic Competition: A Simulation Exercise, Journal of Education and Training, 52(4): 321-339.
22. Bednarek, R. & Ahn, M. 2010. Trilogy Natural Products: Managing a Global Network for Export Growth. International Journal of Case Studies in Management.
23. Ahn, M., York, A., & Rizova, P. 2010. Advancing Biotechnology Convergence: The Parallel Roles of Network Ties and Horizontal Integration, Journal of Commercial Biotechnology. 16(3): 224-238. doi: 10.1057/jcb.2010.4
24. Ahn, M. & Zwikael, O. 2009. Translating Technological Invention into Commercial Innovation: A Project Management Approach, International Journal of Project Management. doi: 10.1016/j.ijproman.2009.11.001
25. Ahn, M. & Bednarek, R. 2009. Setting a Course for Tissue Repair: Mesynthes. Journal of Applied Case Research.
26. Ahn, M., Meeks, M., Davenport, S. & Bednarek, R. 2009. Death of Distance?: Biotechnology Agglomeration Patterns, Alliance Proximity, and Firm Performance, International Journal of Innovation and Technology Management, 6(3): 247-264. Received “Best Paper of 2009” award.
27. Ahn, M. & Bednarek, R. 2009. Going for Growth at Gecko Press. Journal of Applied Case Research.
28. Ahn, M. & York, A. 2009. Resource- and institution-based approaches to biotechnology industry development in Malaysia, Asia Pacific Journal of Management, doi: 10.1007/s10490-009-9147-2
29. Ahn, M., Davenport, S., Meeks, M. & Bednarek, R. 2009. Exploring Technology Agglomeration Patterns for Multinational Pharmaceutical and Biotechnology Firms, Journal of Commercial Biotechnology, 16: 17-32.
30. Ahn, M., Davenport, S., Bromhead, C. & Bednarek, R. 2009. Translating Technological Invention into Global Commercial Innovation: Zygem Corporation. The Management Case Study Journal.
31. Ahn, M., York, A., Loh, M. & Bednarek, R. 2009. Accelerating Biotechnology Industry Growth and Innovation in Malaysia: Identifying Priorities and Building Capabilities. Malaysia Biotech Corporation Research Series.
32. Ahn, M. & Meeks, M. 2008. Building a Conducive Environment for Life Science Based Entrepreneurship and Industry Clusters, Journal of Commercial Biotechnology.14: 20-30.
33. Ahn, M., Ackerley, D., Davenport, S., & Bednarek, R. 2008. Industrial Research Limited: New Zealand-Based Biopharmaceutical Entrepreneurship, The Management Case Study Journal, vol. 8.
34. Ahn, M. 2008. Innovation Matters: The Long Shadows of Black Swans, Innovate, Q4.
35. Ahn, M., Meeks, M., & Bednarek, R. 2008. Managing High Growth (Ad)Ventures: Putting Good Advice to Work in NewZealand Firms, Deloitte & Touche Research Series.
36. Ahn, M. 2008. Financing New (Ad)Ventures, Innovate, Q1.
37. Ahn, M. & Meeks, M. 2008. Anabolic Advice: The Paradox of Managing High Growth Firms, INBusiness.
38. Ahn, M., Meeks, M., Ross, C., Bednarek, R. & Dalziel, S. 2008. Making Biotechnology Work for New Zealand, NZBIOGW Research Series. http://www.nzbio.org/uploaded/MakingBiotechWork.pdf.
39. Ahn, M. & Meeks, M. 2007. Hana Biosciences, Inc.: A Case Study in Biopharmaceutical Entrepreneurship, Journal of Applied Case Research.
40. Ahn, M. 2007. No invitation required: Competing and winning in a global context, Innovate, Q4.
41. Ahn, M., Vitale, F. & Tong, V. 2005. Biopharmaceutical Alliances: It’s All Academic, Biopharmaceutical International.
42. Ahn, M. Adamson, J. & Dornbusch, D. 2004. From Leaders and Leadership: Managing Change, Journal of Leadership and Organizational Studies. 10:4, 112-123.
43. Ahn, M. & Dornbusch, D. 2003. Competency-Based Benchmarking: Revolutionizing Biopharmaceutical Product Launches, Benchmarking: An International Journal. 11. Received “Highly Commended Award” by Literati Club, 2004.
44. Ahn, M. 2003. Organizational Change and Social Capital: Genentech, Inc. Case Study, Institute for Social Capital, University of Notre Dame de Namur.
45. Ahn, M., Grimwood, A., Schwarzwald, H. & Herman, A. 2003. Ethics and the HIV/AIDS Pandemic in the Developing World, Journal of International Association of Physicians in AIDS Care, 2: 2 81-87.
46. Ahn, M., Damonti, J. & Herman, A. 2000. Public Private Partnerships in Healthcare for Developing Countries: A New Paradigm for Change, Managed Care Quarterly. 8:65–72.
47. Ahn, M. 1999. Developing a Profitable Market Share Strategy for Multinational Pharmaceutical Companies in China, Journal of Pharmaceutical Marketing & Management. Winter: No. 13.
48. Ahn, M., Herman, A. & Damonti, J. 1999. Building Public-Private Partnerships in Healthcare for Developing Countries: Towards a New Paradigm, Journal of International Association of Physicians in AIDS Care.
49. Ahn, M. 1999. Secure the Future: Building Public-Private Partnerships in HIV/AIDS in Southern Africa, Global Strategies for the Prevention of HIV Transmission. No. 135.
50. Ahn, M. & H. Liebel. 1992. Managing Strategic Foreign Exchange Exposure for Multinationals, Intermarket. Winter.
51. Ahn, M. & Falloon, W. 1991. Strategic Risk Management: How Global Corporations Manage Financial Risk for Competitive Advantage. Probus Publishing: Chicago.

What I think of the idea behind WebmedCentral and WebmedCentral plus:

Advancing thought leadership by disintermediating a heretofore expensive, bureacratic process of print journals.